Insulin inhalation - Dance Biopharm

Drug Profile

Insulin inhalation - Dance Biopharm

Alternative Names: Dance 501; Dance-01

Latest Information Update: 15 Feb 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Dance Pharmaceuticals
  • Developer Dance Biopharm
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 15 Feb 2016 This programme is still active
  • 01 Dec 2013 Dance Pharmaceuticals completes the phase I/II Samba-02 trial in Type-2 diabetes mellitus in Germany (EudraCT2013-003042-16)
  • 01 Sep 2013 Phase-I/II clinical trials in Type-2 diabetes mellitus in Germany (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top